Overview: What Is PathAI?
PathAI is a digital pathology platform that uses AI to assist anatomic pathologists in primary diagnosis, biomarker quantification, and clinical trial scoring. Founded in 2016 in Boston, PathAI holds three kinds of FDA recognition: a 510(k) clearance for AISight Dx (slide-image viewing and management software, an aid for primary diagnosis, with a Predetermined Change Control Plan for adding cleared displays, scanners and browsers), FDA Drug Development Tool Biomarker Qualification for AIM-MASH AI Assist (qualified under the FDA name AIM-NASH; the first AI pathology tool to receive DDT qualification), and FDA Breakthrough Device Designation for PathAssist Derm.
PathAI's commercial strategy combines lab partnerships (notably the national deployment with Labcorp), pharmaceutical partnerships for clinical trials, and an AI marketplace that hosts third-party algorithms from companies including Mindpeak, Stratipath, and Primaa. This makes PathAI both a software platform and a distribution channel for digital pathology AI.
Key Features
- AISight Dx digital pathology image management system
- Digital slide viewing and management for primary diagnosis (AISight Dx, FDA 510(k))
- AIM-MASH AI Assist for MASH clinical trials
- PathAssist Derm for dermatopathology
- Whole slide image analysis
- Secure cloud-based slide viewing and management
- Integration with laboratory information systems
- AI model marketplace (Mindpeak, Stratipath, Primaa)
Regulatory & Clinical Validation
AISight Dx received FDA 510(k) clearance (K243391) in June 2025 as software for viewing and managing digital images of surgical pathology slides; FDA's indication calls it an aid to the pathologist for primary diagnosis. Its Predetermined Change Control Plan lets PathAI add FDA-cleared displays, scanners, file formats and browsers without a new submission (510(k) summary). The plan does not cover changes to an AI model.
AIM-MASH AI Assist received FDA Drug Development Tool Biomarker Qualification in December 2025 — FDA called it the first AI drug development tool it has qualified. The FDA qualified it under its earlier name, AI-Based Histologic Measurement of NASH (AIM-NASH); PathAI renamed it after the field moved from "NASH" to "MASH". Within its qualified context of use, drug sponsors can use it in MASH (metabolic dysfunction-associated steatohepatitis) trial submissions without resubmitting the tool's validation (per PathAI). It is a drug-development qualification, not a device clearance for clinical care.
PathAssist Derm received FDA Breakthrough Device Designation in March 2026 for dermatopathology (per PathAI). The designation is not a clearance.
Pricing
PathAI does not publish standard pricing. Lab and enterprise customers contract on per-case fees, revenue-share arrangements with reference labs, or platform licensing. Pharma clients pay separately for clinical trial partnerships. Practical implication for buyers: budget for a procurement engagement and a multi-month implementation, not a self-serve subscription.
Pros & Cons
Strengths
- ✓ First AI pathology tool with FDA DDT Biomarker Qualification
- ✓ AISight Dx 510(k) cleared as slide-viewing software for primary diagnosis
- ✓ Labcorp national deployment validates production scale
- ✓ AI marketplace hosts third-party pathology algorithms
- ✓ Strong pharma trial partnerships including AIM-MASH
Weaknesses
- ✗ Niche focus — pathology-only, not broad clinical AI
- ✗ Adoption limited by scanner hardware requirements
- ✗ Enterprise-only with complex deployment
- ✗ Most revenue from pharma partnerships, not direct clinical sales
- ✗ Digital pathology market still in early adoption phase
Who Should Evaluate PathAI?
PathAI is built for anatomic pathology labs adopting digital pathology, reference labs serving large case volumes, pharmaceutical companies running MASH or other biomarker-driven trials, and dermatopathology programs evaluating AI assist tools. It is not relevant for non-pathology clinical settings, small practices without whole-slide imaging infrastructure, or organizations evaluating ambient AI scribes or radiology AI.
Verdict
PathAI is a strong platform to evaluate for any lab serious about digital pathology adoption. The DDT qualification for AIM-MASH was the first FDA qualification of an AI drug development tool. For pharma trial sponsors evaluating MASH biomarker tools, that qualification is the main reason to put PathAI on the shortlist.